155.20
-13.01 (-7.73%)
| Previous Close | 168.21 |
| Open | 168.21 |
| Volume | 1,585,472 |
| Avg. Volume (3M) | 1,232,801 |
| Market Cap | 20,489,658,368 |
| Price / Sales | 12.32 |
| Price / Book | 21.92 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -14.01% |
| Operating Margin (TTM) | -8.94% |
| Diluted EPS (TTM) | -1.76 |
| Quarterly Revenue Growth (YOY) | 63.90% |
| Total Debt/Equity (MRQ) | 54.15% |
| Current Ratio (MRQ) | 4.39 |
| Operating Cash Flow (TTM) | 25.17 M |
| Levered Free Cash Flow (TTM) | -2.23 M |
| Return on Assets (TTM) | -9.96% |
| Return on Equity (TTM) | -25.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Natera, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.40 |
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.52% |
| % Held by Institutions | 93.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Duquesne Family Office Llc | 30 Sep 2024 | 3,566,850 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 200.00 (JP Morgan, 28.87%) | Buy |
| 200.00 (Piper Sandler, 28.87%) | Buy | |
| Median | 162.50 (4.70%) | |
| Low | 135.00 (Bernstein, -13.02%) | Buy |
| Average | 165.80 (6.83%) | |
| Total | 10 Buy | |
| Avg. Price @ Call | 149.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 13 Dec 2024 | 200.00 (28.87%) | Buy | 166.55 |
| 13 Nov 2024 | 160.00 (3.09%) | Buy | 160.97 | |
| Piper Sandler | 18 Nov 2024 | 200.00 (28.87%) | Buy | 153.42 |
| Morgan Stanley | 14 Nov 2024 | 176.00 (13.40%) | Buy | 151.11 |
| Baird | 13 Nov 2024 | 160.00 (3.09%) | Buy | 160.97 |
| Canaccord Genuity | 13 Nov 2024 | 165.00 (6.31%) | Buy | 160.97 |
| 29 Oct 2024 | 150.00 (-3.35%) | Buy | 124.74 | |
| Craig-Hallum | 13 Nov 2024 | 157.00 (1.16%) | Buy | 160.97 |
| TD Cowen | 13 Nov 2024 | 175.00 (12.76%) | Buy | 160.97 |
| Bernstein | 30 Oct 2024 | 135.00 (-13.02%) | Buy | 126.73 |
| Leerink Partners | 17 Oct 2024 | 150.00 (-3.35%) | Buy | 122.35 |
| Goldman Sachs | 16 Oct 2024 | 140.00 (-9.79%) | Buy | 126.77 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHAPMAN ROWAN E | - | 166.45 | -1,767 | -294,117 |
| MOSHKEVICH SOLOMON | 167.80 | 167.80 | 4,217 | 707,613 |
| RABINOWITZ MATTHEW | - | 166.55 | -160,000 | -26,648,000 |
| Aggregate Net Quantity | -157,550 | |||
| Aggregate Net Value ($) | -26,234,505 | |||
| Aggregate Avg. Buy ($) | 167.80 | |||
| Aggregate Avg. Sell ($) | 166.93 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RABINOWITZ MATTHEW | Officer | 13 Dec 2024 | Automatic sell (-) | 160,000 | 166.55 | 26,648,000 |
| CHAPMAN ROWAN E | Director | 10 Dec 2024 | Sell (-) | 1,767 | 166.45 | 294,117 |
| MOSHKEVICH SOLOMON | Officer | 09 Dec 2024 | Acquired (+) | 9,075 | 167.80 | 1,522,785 |
| MOSHKEVICH SOLOMON | Officer | 09 Dec 2024 | Automatic sell (-) | 4,858 | 167.80 | 815,172 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |